Clinical Trial

Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 23, 2026 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase I clinical study to evaluate the safety and tolerability of FAST targeted chimeric antigen receptor (CAR)-T cells (PTC13) in patients with carcinoembryonic antigen (CEA)-positive advanced malignant solid tumors, and to obtain the maximum tolerated dose of FAST CAR-T (PTC13) and phase II Recommended dose.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-02-08; most recent amendment 2026-01-21.
Trial Details
NCT Number NCT06821048
Lead Sponsor Weijia Fang, MD
Collaborators: Chongqing Precision Biotech Co., Ltd
Conditions Colorectal Cancer, Stomach Cancer, Pancreatic Cancer, Metastatic Cancer
Enrollment 18 participants
Start Date 2024-07-24
Primary Completion 2026-06-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-23